Tvardi Therapeutics/$TVRD
1D1W1MYTD1Y5YMAX
Capital at risk
About Tvardi Therapeutics
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
- Ticker
- $TVRD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 12
- Headquarters
- Sugar Land, United States
- Website
- tvarditherapeutics.com
TVRD Metrics
BasicAdvanced
$22M
-
-$2.77
-
-
Price and volume
Market cap
$22M
52-week high
$43.65
52-week low
$1.50
Average daily volume
159K
Financial strength
Current ratio
1.873
Quick ratio
1.73
Long term debt to equity
0.003
Total debt to equity
0.017
Profitability
EBITDA (TTM)
-27.11
Management effectiveness
Return on assets (TTM)
-55.51%
Return on equity (TTM)
-126.19%
Valuation
Price to book
1.81
Price to tangible book (TTM)
1.88
Price to free cash flow (TTM)
-0.608
Free cash flow yield (TTM)
-164.43%
Free cash flow per share (TTM)
-2.664
Growth
Earnings per share change (TTM)
-63.97%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.